A Phase IIb, Multicenter, Randomized, Parallel-group, Double- blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia

Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability., which is a major risk factor for Cardiovascular Disease (CVD)

Percent change from baseline of Low-Density Lipoprotein cholesterol (LDL-C) at Week 12

Percent change from baseline of Low-Density Lipoprotein cholesterol (LDL-C) at Week 12, AZD0780 plasma concentrations summarized by sampling timepoint, Percent change from baseline at Week 12 in, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-high-density lipoprotein cholesterol (Non-HDL-C), very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A-1 (ApoA1), apolipoprotein B-100 (ApoB), lipoprotein (a) (Lp(a)), remnant cholesterol, and high-sensitivity C-reactive protein (hsCRP)., Percent change from baseline at Week 12 in, total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-high-density lipoprotein cholesterol (Non-HDL-C), very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A-1 (ApoA1), apolipoprotein B-100 (ApoB), lipoprotein (a) (Lp(a)), remnant cholesterol, and high-sensitivity C-reactive protein (hsCRP)., Safety and tolerability will be assessed in terms of adverse events, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations

No related papers found yet.

Czechia, Denmark, Hungary, Slovakia, Spain